TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05471830
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No drug will be provided to participants. Patients follow routine clinical practice/administration.
Study: NCT06416709
Drug: mesenchymal stem cells
Normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times
Study: NCT06088147
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A standard derma pen 12 pins with of 0,5 mm depth was used, will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution
Study: NCT05631990
Drug: AD-209
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT05631990
Drug: AD-209-1A
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT05631990
Drug: AD-209-1B
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT05280470
Drug: Ifinatamab Deruxtecan (I-DXd)
Normalized name: Trastuzumab deruxtecan
DrugBank: Ifinatamab deruxtecan (DB18212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
Study: NCT06060015
Drug: 5mg bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
Study: NCT06060015
Drug: 10mg bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
Study: NCT05635305
Drug: Zoliflodacin Patheon
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)
Study: NCT00061152
Drug: Capsaicin Dermal Patch
Normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05610969
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
Study: NCT05916339
Drug: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication
Normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)
Study: NCT05233332
Drug: HL-085
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12mg BID HL-085
Study: NCT05233332
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 720mg BID Vemurafenib
Study: NCT05342506
Drug: Toripalimab + ScTIL
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
Study: NCT00001084
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001084
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001084
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001084
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002332
Drug: Thymopentin
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05222724
Drug: Brufen
Normalized name: Brufen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
Study: NCT05174455
Drug: Niraparib Tosylate Monohydrate
Normalized name: Niraparib tosylate monohydrate
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05442905
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia will be induced with propofol 2-3mg/kg
Study: NCT05442905
Drug: Atracurium Besylate
Normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atracurium 0.15mg/kg used for muscle relaxation before intubation
Study: NCT05442905
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane(1%-2%) used during anesthesia
Study: NCT06507332
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
Study: NCT01674738
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 i.v. on day 1 (three-week cycle)
Study: NCT05802225
Drug: BCD-178
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: at an initial dose of 840 mg (1 cycle), then 420 mg
Study: NCT05802225
Drug: Perjeta
Normalized name: Perjeta
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: at an initial dose of 840 mg (1 cycle), then 420 mg
Study: NCT01674738
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 i.v. on day 1 (three-week cycle)
Study: NCT01674738
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7,5 mg/kg i.v. on day 1 (three-week cycle)
Study: NCT04781725
Drug: INT230-6
Normalized name: INT230-6 COMPONENT CISPLATIN
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
Study: NCT06414837
Drug: HR091506 tablets + placebo of febuxostat tablets
Normalized name: Febuxostat Tablets
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.
Study: NCT05929456
Drug: Cetuximab-IRDye800
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
Study: NCT05263453
Drug: HL-085
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
Study: NCT05263453
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
Study: NCT06414837
Drug: febuxostat tablets + placebo of HR091506 tablets
Normalized name: Febuxostat Tablets
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
Study: NCT05162768
Drug: Elamipretide
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
Study: NCT06378489
Drug: Etonogestrel implant
Normalized name: Etonogestrel Implant
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The etonogestrel implant will be inserted on the inner side of the non-dominant upper arm of the patient. Three months after insertion, a repeat transvaginal ultrasound will be performed to document endmetrial thickness and an endometrial biopsy will also be done using the Pipelle to document the histology of the endometrium. If the biopsy showed regression of the hyperplasia, the implant will be left in place for a minimum of 12 months until 3 years. If the repeat biopsy showed non-resolution of the hyperplasia, the patient will be referred to a gynecologic oncologist for further management
Study: NCT05336812
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05336812
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05688345
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
Study: NCT05688345
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
Study: NCT05688345
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
Study: NCT05721404
Drug: Icodextrin Peritoneal Dialysis Solution
Normalized name: Icodextrin Peritoneal Dialysis Solution
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin (Extraneal) for long night dwell
Study: NCT05721404
Drug: Hypertonic Dextrose solution
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic Dextrose solution for long night dwell
Study: NCT05786430
Drug: Lazertinib/Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
Study: NCT01630902
Drug: Torrent's Felodipine Extended-Release Tablets
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02127684
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab 0.3mg intravitreally monthly
Study: NCT02127684
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab given every 2 weeks for 8 weeks then monthly as needed
Study: NCT05976893
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocuma:420 mg every 4 weeks
Study: NCT05493215
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
Study: NCT00015704
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05426746
Drug: ALT-100
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of drug substance diluted in 0.9% normal sterile saline
Study: NCT04985968
Drug: Cobitolimod 250 mg
Normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal administration
Study: NCT05299866
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
Study: NCT04985968
Drug: Cobitolimod 500 mg
Normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal administration
Study: NCT04916080
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
Study: NCT05703997
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg administered intravenously.
Study: NCT04733521
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin 75mg/m2 on day 1 of 21-day cycle
Study: NCT05663879
Drug: Compound-X
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Compound-X
Study: NCT06434025
Drug: Iron Carboxymaltose
Normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iron Carboxymaltose 500 mg. 2 vials administered IV.
Study: NCT06434025
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg Tab, PO, onde a day.
Study: NCT06434025
Drug: Placebo of Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
Study: NCT05664516
Drug: TNX-1900 (Tonix Pharmaceuticals)
Normalized name: Ellis Tonic
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxytocin nasal spray
Study: NCT05565222
Drug: Piperacillin/tazobactam or temocillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)
Study: NCT06060704
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
Study: NCT05565222
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 g every 8 hours by intravenous route (adjusted in case of renal failure)
Study: NCT05435768
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days
Study: NCT06060704
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
Study: NCT05743764
Drug: HU007
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cyclosporine 0.02%, trehalose 3%
Study: NCT05743764
Drug: Restasis
Normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine 0.05%
Study: NCT05743764
Drug: Moisview Eye drop
Normalized name: NIACINAMIDE 2 g in 100 mL TOPICAL LIQUID [MOISTIE PURE ESSENCE]
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trehalose 3%
Study: NCT04937972
Drug: SHR-1701 Combined With Fluazopalil
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SHR-1701 +fluzoparib
Study: NCT04280471
Drug: Fecal Microbiota Transplantation Capsule
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive OpenBiome FMT Capsule DE PO
Study: NCT06126731
Drug: Enzalutamide 40mg
Normalized name: ENZALUTAMIDE 40MG CAP
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
Study: NCT06126731
Drug: Amoxicillin 500mg
Normalized name: AMOXICILLIN 500MG CAP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder
Study: NCT06126731
Drug: Metronidazole 400mg
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other
Study: NCT06126731
Drug: Vancomycin 125mg
Normalized name: VANCOMYCIN 125MG/2.5ML (50MG/ML) ORAL
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass
Study: NCT06126731
Drug: Ciprofloxacin 500g
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side
Study: NCT00036023
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04973904
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04973904
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04973904
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04973904
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT06134635
Drug: Statins
Normalized name: Endostatins
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
Study: NCT06134635
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab 140mg twice a month, subcutaneous injection
Study: NCT06452342
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
Study: NCT05727969
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
Study: NCT05727969
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
Study: NCT06132243
Drug: Jaktinib Hydrochloride Tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, one tablet at a time
Study: NCT04821063
Drug: Moxifloxacin Hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 400 mg; Dosage form: tablet; Route of administration: oral
Study: NCT04788017
Drug: Ziresovir
Normalized name: Ziresovir
DrugBank: Ziresovir (DB15145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir